国家药监局拟规定:第三方平台不能直接网络销售药品

2022-06-26 好医生 好医生

目前涉及药品网络交易第三方平台的互联网处方药销售模式主要分为三种,一是,医药分离模式,指医疗机构仅负责诊疗,开具处方、审方,不提供药品及配送。

随着互联网行业的迅猛发展,电子商务几乎渗透到到各个行业,医药领域也不例外。不过,医疗行业直接关乎人的生命健康,有别于其他行业。随着相关的监管制度日益完善,电子商务与医疗的融合是否能迎来像其他行业一样的“黄金时代”或许是个“未知数”。

近期,国家药监局公布的《中华人民共和国药品管理法实施条例(修订草案征求意见稿)》(简称《意见稿》),为时一个月的公开征求意见已正式截止。

 

图片

图片来源:国家药监局

其中,此版《意见稿》在药品经营章节对第三方平台管理义务提出“第三方平台提供者不得直接参与药品网络销售活动。”的要求,引起业界广泛关注。

 

图片

图源:中华人民共和国药品管理法实施条例(修订草案征求意见稿)

疫情催生医药电商市场扩增

疫情以来,线上诊疗迅速扩增,这也催生了医药电商行业的迅猛发展。据米内网统计,2021年我国网上药店市场药品销售额达368亿元,同比增长51.49%。

涉足医药领域的互联网平台相关数据也证实这一点,以国内规模较大的互联网平台为例。

有报道称,根据2021年财报显示,京东健康全年收入307亿元,其中以京东大药房为主要载体的自营收入为262亿元,占比为85.34%。

而阿里健康2022年年报也显示,医药营收占了阿里健康总营收的“半壁江山”,报告期内,阿里健康医药自营业务收入达179.1亿元,同比增长35.5%。其中,以阿里健康品牌运营的自营药房药品收入占比达到64%,处方药业务收入增长105.2%。

上述两者都目前都涉及非处方药的网上零售,以“自营+平台”等形式展开,其中“自营”业务收入占也都比较大。如果《意见稿》真的正式实施,对于涉足医药电商行业的互联网平台,或许都将从新开始寻求医疗方面的业务模式。

阿里健康京东健康股价跌超9%

近期,随着《意见稿》公开征求意见截至,医药电商业务相关的互联网平台疑似都受到波及。据第一财经报道称,6月22日上午,阿里健康(00241.HK)、京东健康(06618.HK)股价突然出现暴跌,盘中跌幅均超过9%。这些企业的股价波动跟第三方平台将禁止自营药品消息有关。

对此,医药电商行业的相关从业者在接受第一财经报采访时表示,“近期有关部门也召开了研讨会讨论上述事宜,但‘第三方平台提供者不得直接参与药品网络销售活动第三方平台提供者不得直接参与药品网络销售活动’的规定最后能否落实,还存在一定的不确定性。”,这意味着目前相关企业已注意到《意见稿》中的要求,暂时正处于观望动态。

报道还称,对于次变动,第三方医药行业观察人士则认为,如果未来第三方平台提供者不得直接参与药品网络销售活动相关征求意见的出台,将进一步催化线下药店与线上平台之间的利益之争,直接利好线下药店的发展。

加强第三方平台监管已成一大趋势

对于《意见稿》是否会落定第三方平台禁止参与药品网络销售活动,一些企业正认为仍具有不确定性。那么,医疗法律领域的专业人士怎么看呢?

“加强对第三方平台的监管已经成为一大趋势。”据21世纪经济报报道,中国卫生法学会常务理事、北京市华卫律师事务所副主任邓利强在接受采访时说。

邓利强介绍,近年来,网上购药已经成为社会大众依赖的一种模式。但与此同时,一些案例也表明,在网上购药可能会出现虚假药店、不合格药店、虚假广告等问题,导致患者很有可能购买到并不合规的药品。由于医药电商本质是流量主导的市场,拥有大流量的第三方平台一直是这个市场的主流,因此,相应的监管措施也将会跟进。

邓利强还进一步指出,目前涉及药品网络交易第三方平台的互联网处方药销售模式主要分为三种,一是,医药分离模式,指医疗机构仅负责诊疗,开具处方、审方,不提供药品及配送。该模式有两种运行方式。第一种方式是医院医师负责线上诊疗开处方,医院可以签约药品网络交易第三方平台的药店负责提供药品、配药和物流配送。第二种方式是医院医师线上诊疗开处方,将处方直接交给患者,患者自己选择在线上或线下药店买药。

二是,电商平台办互联网医院处方药销售模式,指患者在电商平台发起购药申请,电商平台开办的互联网医院负责线上开处方、审核处方,由其平台药店药师审核处方并提供药品、配药、配送的模式。

三是,电商平台处方药销售模式,指电商平台没有互联网医院,在销售处方药时,通过委托互联网医院的医师代为咨询开处方,处方进入药店,由药店药师审核处方,提供药品,再进行配药、配送。

“在这三种模式背后,也存在诸多的问题亟待解决。例如,在第一种模式之下,参与合作服务主体和环节较多,容易产生纠纷后推卸责任。医院对签约平台监管薄弱。提供药品的药店是否有真实的药师审核处方,也是存疑。也存在药店药品的保管和质量安全问题。所以,加强对于药品网络交易第三方平台的监管具有重要意义。”邓利强说。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-06-28 ms3000001032506732

    估计又是动了某某的蛋糕

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-06-28 EltaMD昵称)

    这样就难搞喔!其实要放开才对。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-06-28 xuyu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1949618, encodeId=410c1949618a0, content=<a href='/topic/show?id=c466e57725a' target=_blank style='color:#2F92EE;'>#第三方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75772, encryptionId=c466e57725a, topicName=第三方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Mar 01 12:33:52 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046614, encodeId=697220466140e, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Apr 15 20:33:52 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 26 11:33:52 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229081, encodeId=146a122908166, content=估计又是动了某某的蛋糕 , beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd775476685, createdName=ms3000001032506732, createdTime=Tue Jun 28 07:40:55 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229080, encodeId=aa5d12290804c, content=这样就难搞喔!其实要放开才对。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220511/f42ace9635514ccaa5596518c08beb19/93d7d528c2fa4c58b823ae7487c9e1aa.jpg, createdBy=54ee2384025, createdName=EltaMD昵称), createdTime=Tue Jun 28 07:35:06 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301754, encodeId=0d891301e5458, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429288, encodeId=af01142928880, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Jun 28 05:33:52 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

相关资讯

日本发布《2019年医药代表白皮书》

近日,日本MR认证中心发布了《2019年版医药代表白皮书》,截至今年 3月底,日本医药代表总人数为59900人。

医药代表的收入,减少了吗?

4+7带量采购给药企带来的震荡此起彼伏,4+7全国扩面紧随其后。带量采购实行以来,怎样改变药企营销呢?

带量采购会怎样改变销售药品的方法和人?

昨天的全国药品联盟带量采购结果公布,在医药圈掀起一波波的浪花,让大家充分领略了竞标直播的威力:你看相关股票的涨跌,立马就知道谁家中了,谁家没中。

处方外流:上海医药、九州通、国大药房做了啥布局

围绕处方外流,药企、流通企业、零售企业等进行了诸多尝试,开始跑马圈地。

8大危机,干掉大批药企、药代

今年过半,有好有坏,下半年暗流涌动,医药行业8大危机袭来!

一位日本医药代表的一天

今晚要提到的日本制药是一家总部位于东京的药企,目前有员工 389 人,2018 年的营业收入约 1.7 亿美元,可以看到,规模和其他日企相比属于比较小型的企业。